Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports from H. Navabi et al highlight recent research in cancer vaccines
February 10th, 2009
According to recent research published in the journal Vaccine, "Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyl:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse." "We have evaluated a clinical grade, non-toxic analogue of polyl:C, poly(I:C12U) (Ampligen (R)), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation Of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40...
Source: Cancer Weekly (2009-02-10)
|
